| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
GE HealthCare Technologies Inc.$64.7
0 (0%)
B 73Pipeline Score MedTech · Commercial
Market Cap
29.22 B
EPS
4.19
P/E Ratio
15.38 $
Value Trade
264.91 M
SEC Financials
Q1 2026Dilution Risk
Revenue
5.13 B
R&D Expenses
345.00 M
Operating CF
290.00 M
Total Assets
37.13 B
Total Liabilities
26.23 B
Equity
10.67 B
D/E Ratio
12,345
2.98 %
Week
-11.84 %
1 Month
-22.43 %
3 Month
-14.23 %
6 Month
1.95 %
5 Year
1.95 %
All Time
Cash Data
Cash Position
2.29 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 29, 2026
Overview
Volume
2.56 M
52 Week Range
58.75 - 89.77
% held by Insiders
0.3 %
% held by Institutions
89.43 %
Enterprise Value
37.74 B
Total Shares
456.34 M
Short %
3.16 %
Float Shares
455.42 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for GE HealthCare Technologies Inc.
48Total events
4Upcoming
17Tier-1 (high impact)
2023 – 2026Coverage
Upcoming catalysts 4
Event history 44
Apr 29, 2026
◆Management ChangeCorporate
Phil Rackliffe appointed President and CEO of Advanced Imaging Solutions
Apr 17, 2026
▲Partnership / LicenseCorporate
Expanded collaboration with DeepHealth to extend global access to AI-powered breast cancer screening solutions
breast cancer screeningsource ↗
Apr 17, 2026
●Oral PresentationPresentation
Showcase latest women's health innovations at Society of Breast Imaging Annual Symposium
breast cancer screeningsource ↗
Q2 2026
◆Quarterly UpdateCorporate
Recast financial results for new segment structure expected in Q2 2026 earnings release
Mar 27, 2026
▲Partnership / LicenseCorporate
GE HealthCare announces lead industrial role in COMPASS consortium
cardio-oncologysource ↗
Mar 26, 2026
▲Partnership / LicenseCorporate
GE HealthCare to lead industrial role in EU-funded IHI consortium for cardio-oncology care
cardio-oncologysource ↗
Mar 25, 2026
▲Partnership / LicenseCorporate
Agreement with Gentuity to connect customers with Gentuity HF-OCT and Vis-Rx PRIME Micro-Imaging Catheter
cardiac catheterizationsource ↗
Mar 25, 2026
▲Product LaunchReadyFixPost-Market
U.S. launch of ReadyFix fleet management solution for MAC VU360 ECG workstations
cardiac caresource ↗
Mar 25, 2026
●Oral PresentationPresentation
Showcase of cardiology portfolio at ACC.26 conference
cardiologysource ↗
Mar 23, 2026
Drug Pipeline Intelligence
B73
Pipeline Score $12.3B
Pipeline ValueValuation Signal
29
Drugs Scored1.4x
rNPV / MCap Top 95%
Mid Cap (rank 47 of 911)
Percentile RankGE HealthCare Technologies Inc. holds a solid B-grade pipeline (73/100), with $14.5B risk-adjusted pipeline value, led by Perflutren lipid microsphere in Prostate Carcinoma (Phase 3), across $198B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Perflutren lipid microsphere Small molecule | Prostate Carcinoma | Phase 3 | NCT06024772 | 46% | $3.1B | NOT YET_RECRUITING | 300 | - | - | Feb 1, 2027 | - | May 21, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GEHC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GEHC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-10 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-10 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-10 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GEHCGE HealthCare to announce second quarter 2026 results on July 29, 2026
GE HealthCare will announce its second quarter 2026 financial results on July 29, 2026, before the market opens. The management team will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day. Investors can access the live webcast through the company's investor relations website.
Read more →GEHCGE HealthCare announces cash dividend for second quarter of 2026
GE HealthCare has announced a cash dividend for the second quarter of 2026. This decision reflects the company's ongoing commitment to returning value to its shareholders. However, the article does not provide further details on the dividend amount or other financial implications.
Read more →GEHCESTRO 2026 Congress: GE HealthCare to spotlight AI-enabled solutions to advance precision care across radiation therapy and image-guided interventions
GE HealthCare is set to showcase its AI-enabled solutions at the ESTRO 2026 Congress. The focus will be on advancing precision care in radiation therapy and image-guided interventions. This event highlights the company's commitment to integrating technology into healthcare practices.
Read more →GEHCGE HealthCare next-gen SIGNA MR technology helps advance research discovery and translate innovation into clinical impact
GE HealthCare has introduced next-generation SIGNA MR technology aimed at enhancing research discovery and translating innovations into clinical applications. The new technology is designed to improve imaging capabilities, which could lead to better patient outcomes. However, specific details about the technology's features and clinical impact are not provided.
Read more →GEHC▼ -13.2%on this news
GE HealthCare reports first quarter 2026 financial results
GE HealthCare reported its first quarter 2026 financial results, showing a revenue increase of 7.4% to $5.1 billion, driven by strong performance in Pharmaceutical Diagnostics and Imaging. However, profitability was affected by supplier issues and rising costs, prompting a cautious reduction in profit outlook. The company remains optimistic about future growth through innovation and customer demand.
Read more →GEHC▼ -13.2%on this news
GE HealthCare announces executive team and operational updates to enhance execution, accelerate innovation, and drive growth
GE HealthCare has announced significant changes to its executive team and operational structure to enhance growth and innovation. Phil Rackliffe has been appointed CEO of the new Advanced Imaging Solutions segment, while Catherine Estrampes will lead Global Markets. These changes aim to streamline operations and improve patient care, although they come with the departure of a key leader.
Read more →GEHCGE HealthCare expands mammography collaboration with RadNet’s DeepHealth subsidiary to extend global access to DeepHealth’s AI-powered breast cancer screening solutions
GE HealthCare has expanded its collaboration with DeepHealth to enhance AI-powered mammography tools. This partnership aims to improve breast cancer screening globally by integrating advanced technologies into existing workflows. The initiative builds on previous efforts to increase detection rates and operational efficiency in breast imaging. The collaboration was announced at the Society of Breast Imaging Annual Symposium.
Read more →GEHCGE HealthCare to announce first quarter 2026 results on April 29, 2026
GE HealthCare is set to announce its first quarter results for 2026 on April 29, 2026. This announcement is part of the company's regular financial reporting schedule. Investors and stakeholders will be looking for insights into the company's performance during this period.
Read more →GEHCGE HealthCare Recommends Shareholders Reject “Mini-Tender” Offer by Potemkin Limited
GE HealthCare Technologies Inc. has advised its shareholders to reject an unsolicited mini-tender offer from Potemkin Limited. The offer seeks to purchase 100,000 shares at $45.80 each, which is considerably lower than the recent market price of $70.25. The company emphasizes the risks associated with accepting such offers.
Read more →GEHCGE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe
GE HealthCare has announced its leadership role in the COMPASS consortium, a five-year initiative aimed at enhancing cardio-oncology care across Europe. With a budget of €50.5 million, the consortium focuses on improving early detection of cardiovascular risks in cancer patients. The initiative seeks to integrate various healthcare disciplines to address cardiotoxicity challenges effectively.
Read more →GEHCRiassunto: GE HealthCare annuncia che rivestirà un ruolo industriale leader nel più grande consorzio IHI finanziato dall'UE per la promozione delle cure in ambito cardio-oncologico in Europa
GE HealthCare has announced its leading role in the largest EU-funded consortium focused on promoting cardio-oncology care in Europe. This initiative aims to enhance healthcare delivery in this specialized field. The consortium represents a significant collaboration among various stakeholders in the healthcare sector.
Read more →GEHCGE HealthCare annonce qu’elle va jouer un rôle de premier plan au sein du plus grand consortium de l’IHI financé par l’UE visant à faire progresser les soins cardio-oncologiques à travers l’Europe
GE HealthCare has announced its prominent role in the largest EU-funded consortium focused on advancing cardio-oncological care across Europe. This initiative aims to improve healthcare delivery and innovation in the field. The collaboration is expected to bring together various stakeholders to enhance patient outcomes in cardio-oncology.
Read more →GEHCGE HealthCare verkündet leitende industrielle Rolle im größten von der EU finanzierten IHI-Konsortium zur Förderung der kardio‑onkologischen Versorgung in Europa
GE HealthCare has announced a leading industrial role in the largest EU-funded IHI consortium aimed at enhancing cardio-oncology care in Europe. This initiative reflects the company's commitment to improving healthcare delivery in this specialized field. The consortium's focus is on integrating innovative solutions to advance patient care.
Read more →GEHCSamenvatting: GE HealthCare kondigt zijn leidende industriële rol aan in het grootste, door de EU gefinancierde IHI-consortium om cardio-oncologiezorg in Europa te bevorderen
GE HealthCare has announced its leading role in the largest EU-funded IHI consortium aimed at enhancing cardio-oncology care in Europe. This initiative is expected to significantly impact the healthcare landscape by improving patient outcomes in this specialized field. The consortium represents a collaborative effort to address the challenges in cardio-oncology.
Read more →GEHCResumen: GE HealthCare anuncia un papel industrial líder en el mayor consorcio financiado por la UE en el marco de la IHI para impulsar la atención cardio-oncológica en toda Europa
GE HealthCare has announced its leadership role in the largest EU-funded consortium under the Innovative Health Initiative (IHI) aimed at enhancing cardio-oncology care across Europe. This initiative is expected to drive advancements in healthcare delivery and patient outcomes in this specialized field.
Read more →GEHCGE HealthCare to showcase comprehensive cardiology portfolio at ACC.26, including its latest AI-enabled imaging technologies, advanced software solutions, and key collaborations
GE HealthCare will present its advanced cardiology portfolio at ACC.26, featuring AI-enabled imaging technologies and software solutions aimed at improving patient care. The company emphasizes innovations like the Photonova™ Spectra for enhanced cardiac imaging and the ReadyFix™ solution for operational efficiency. Collaborations with Gentuity will also be highlighted to enhance procedural capabilities in the cath lab.
Read more →GEHCGE HealthCare’s Photonova Spectra photon-counting CT receives FDA clearance
GE HealthCare has announced that its Photonova Spectra photon-counting CT has received 510(k) clearance from the FDA. This advanced imaging solution features the company's Deep Silicon detector technology, providing ultra-high definition spatial and spectral imaging. The device is designed to be flexible, accommodating various clinical needs.
Read more →GEHCGE HealthCare appoints medtech leader Kevin Lobo to Board of Directors
GE HealthCare has appointed Kevin A. Lobo, CEO of Stryker Corporation, to its Board of Directors, effective March 13. Lobo's extensive experience in medical technology and leadership roles positions him to enhance GE HealthCare's strategic initiatives. His appointment is seen as a move to bolster the company's focus on innovation and personalized healthcare.
Read more →GEHCGE HealthCare to showcase AI and digital leadership at HIMSS 2026
GE HealthCare will present its latest innovations at the HIMSS 2026 conference in Las Vegas, focusing on AI and digital solutions to enhance patient care. The company aims to address workforce shortages and streamline healthcare operations through advanced technology. GE HealthCare continues to lead in AI-enabled medical devices, with numerous FDA authorizations. The event will highlight their commitment to improving data exchange and clinical decision-making.
Read more →GEHCGE HealthCare builds on BARDA collaboration with approximately $35 million expansion to advance artificial intelligence-powered ultrasound for trauma care and emergency preparedness
GE HealthCare has announced a $35 million expansion of its contract with BARDA to advance AI-powered ultrasound technology for trauma care. This collaboration aims to enhance diagnostic capabilities and improve patient outcomes in emergency settings. The project will also involve engaging clinicians to validate the technology's effectiveness in real-world scenarios.
Read more →GEHCGE HealthCare management to present at upcoming investor conferences
GE HealthCare announced that its management team will present at several upcoming investor conferences. The presentations will be accessible via webcasts on the company's website. GE HealthCare continues to innovate in medical technology and has been recognized as one of Fortune's Most Admired Companies.
Read more →GEHCGE HealthCare management to present at upcoming investor conferences - February 12, 2026
GE HealthCare has announced that its management team will present at several upcoming investor conferences. The webcasts for these events will be accessible on the company's website. GE HealthCare is recognized for its innovations in medical technology and has been named one of Fortune's Most Admired Companies.
Read more →GEHCGE HealthCare launches ReadyFix fleet management solution to help enhance operational efficiency and reliable patient care
GE HealthCare has launched ReadyFix, a remote fleet management solution aimed at enhancing device uptime in healthcare systems. This tool integrates with the MAC VU360 ECG workstations, providing real-time data for device diagnostics and maintenance. The initiative addresses the increasing complexity of managing medical devices and aims to improve the reliability of cardiac care. ReadyFix is part of GE's broader strategy to support biomedical engineers in delivering consistent patient care.
Read more →GEHCGE HealthCare reports fourth quarter and full year 2025 financial results
GE HealthCare reported strong financial results for Q4 and full year 2025, exceeding expectations in topline and earnings per share. The company highlighted growth in key areas such as Pharmaceutical Diagnostics and Imaging, alongside a robust innovation pipeline for 2026. Leadership emphasized operational resilience and a commitment to delivering shareholder value despite a dynamic macro environment.
Read more →GEHCGE HealthCare announces U.S. FDA 510(k) clearance and CE Mark for Allia Moveo and marks first global installation, advancing precision care in the interventional suite
GE HealthCare announced that its Allia Moveo platform has received FDA 510(k) clearance and CE Marking, marking a significant advancement in interventional care. The first installation occurred at Hôpital Marie-Lannelongue in France, followed by Baylor St. Luke's Medical Center in the U.S. The system promises enhanced mobility, precision, and workflow efficiency for clinicians.
Read more →GEHCGE HealthCare to announce fourth quarter and full year 2025 results on February 4, 2026
GE HealthCare will announce its fourth quarter and full year 2025 financial results on February 4, 2026. The announcement will occur before the market opens, followed by a conference call and webcast at 8:30 a.m. ET. The company's commitment to innovation in healthcare solutions is highlighted, alongside its recognition as a top admired company.
Read more →GEHCGE HealthCare management to present at upcoming investor conference
GE HealthCare announced that its management team will present at the JP Morgan 44th Annual Healthcare Conference on January 13, 2026. The presentation will be accessible via a webcast on the company's investor relations website. GE HealthCare continues to be a leader in healthcare technology and services.
Read more →GEHCGE HealthCare introduces advanced imaging solutions powered by NVIDIA technology to support timely diagnoses and streamlined clinical workflows
GE HealthCare is showcasing advanced imaging solutions at the RSNA 2025 Annual Meeting, developed in collaboration with NVIDIA. This partnership aims to enhance medical imaging through AI and accelerated computing, addressing challenges in diagnostics and workflows. Innovations include autonomous X-ray and ultrasound technologies to improve efficiency and patient care.
Read more →GEHCGE HealthCare builds on a century of innovation to shape the future of radiology at RSNA 2025
At RSNA 2025, GE HealthCare will unveil over 40 innovative technologies aimed at enhancing radiology and addressing industry challenges. The company emphasizes its commitment to precision care through AI and cloud-enabled solutions, backed by a significant investment in research and development. GE HealthCare's legacy of innovation continues as it strives to improve operational efficiency and patient outcomes.
Read more →GEHCGE HealthCare unveils next-generation SIGNA MRI technology, aiming to boost efficiency, enhance patient experience, and advance sustainability
GE HealthCare has announced the submission of 510(k) applications to the FDA for its next-generation SIGNA MRI technology. This includes the SIGNA Bolt and SIGNA Sprint systems, which aim to improve diagnostic precision, enhance patient outcomes, and promote sustainability in MRI practices. The technology features AI-driven workflows and is designed to address the increasing demands on radiology departments.
Read more →GEHCGE HealthCare unveils Pristina Recon DL for mammography – deep learning image reconstruction technology delivering clearer image quality
GE HealthCare has received FDA Premarket Authorization for its new Pristina Recon DL technology, which enhances 3D mammography image quality using deep learning. This innovation aims to improve early detection and diagnosis of breast cancer, addressing the rising burden of the disease. The system has shown superior performance in clinical trials, preferred by radiologists for its clarity and consistency.
Read more →GEHCGE HealthCare Technologies Inc. Prices Secondary Offering of 13,281,302 Shares
GE HealthCare Technologies Inc. announced the pricing of a secondary underwritten public offering of 13,281,302 shares of common stock. The offering is being conducted by Morgan Stanley as the selling stockholder, with no proceeds going to GE HealthCare. The closing of the offering is expected on November 12, 2024, pending customary closing conditions. This move includes a debt-for-equity exchange with GE Aerospace, potentially impacting financial outlook for the company.
Read more →GEHCare supplemental measures of our performance that we believe will help investors understand our results of operations, and assess our future prospects. When read in conjunction with our U.S. GAAP results, these non-GAAP
GE HealthCare (GEHC) announced a significant restructuring effective July 1, 2024, which will realign its Image Guided Therapies (IGT) from the Imaging segment to the newly renamed Advanced Visualization Solutions (AVS) segment. This change is intended to better match clinical usage and enhance business impact. The AVS segment will encompass two core areas, Specialized Ultrasound and Procedural Guidance, reflecting the evolving needs of healthcare providers and patients.
Read more →GEHCGE HealthCare Technologies Inc. Prices Upsized Secondary Offering of 15,000,000 Shares
GE HealthCare Technologies Inc. announced the pricing of an upsized secondary offering of 15,000,000 shares at $86.00 each, increasing from an initially planned 10,000,000 shares. GE Aerospace will exchange shares for indebtedness held by Morgan Stanley, which will serve as the selling stockholder during the offering. Morgan Stanley and Citigroup are the lead managers for this transaction, set to close on September 16, 2024, subject to customary conditions. The offering is backed by a shelf registration statement with the SEC, allowing for the issuance of new shares.
Read more →GEHCGE HealthCare Technologies Inc. Prices Upsized Secondary Offering of 14,000,000 Shares
GE HealthCare Technologies Inc. announced the pricing of a secondary public offering of 14 million shares, increased from the originally planned 13 million. The company will not sell any of its own shares nor receive proceeds from the offering, which is underwritten by Morgan Stanley. This offering is set to close on March 15, 2024, pending regulatory approvals. The offering highlights ongoing market activities and investor interest in GE HealthCare's stock.
Read more →GEHCGE HealthCare Technologies Inc. Commences Secondary Offering of 13,000,000 Shares
GE HealthCare Technologies Inc. has announced a secondary public offering of 13 million shares of its common stock, which will not generate proceeds for the company. Instead, shares will be exchanged for indebtedness held by Morgan Stanley affiliates. Major financial institutions are managing the sale, reflecting confidence in the market. The registration statement for this offering has been filed with the SEC, making it a significant event for investors.
Read more →GEHCGE HealthCare Names James Saccaro Vice President and Chief Financial Officer Chicago, IL
GE HealthCare has appointed James Saccaro as its new Vice President and Chief Financial Officer, effective June 1, 2023. Saccaro, previously with Baxter International, brings a wealth of experience in the medtech and bioscience sectors. He succeeds Helmut Zodl, who will stay on to lead special projects related to the company's separation from GE. GE HealthCare President and CEO Peter Arduini expressed excitement about Saccaro's role in executing the company’s strategic growth and delivering value to shareholders.
Read more →GEHCForward-looking Statements This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as "will," "expect," "may," "would," "could," "pla
GE HealthCare reported preliminary revenue results for Q4 and full year 2022, showing strong growth and a positive outlook for 2023. The company's Q4 revenue was approximately $4.9 billion, reflecting a 7% year-over-year growth and a notable 12% organic growth. The management remains optimistic about continued revenue growth, an expected EBIT margin increase, and improving supply chain conditions. GE HealthCare plans to present detailed results and outlook at the upcoming J.P. Morgan Healthcare Conference.
Read more →GEHCGE HealthCare Completes Spin-Off and Begins Trading on Nasdaq A leader in precision care, focused on creating a world where healthcare has no limits Attractive financial profile supported by commitment to accelerating gr
GE HealthCare has completed its spin-off from General Electric and commenced trading on Nasdaq under the ticker GEHC. The company aims to establish itself as a global leader in precision care, backed by significant financial resources and a commitment to digital innovation. With a strong presence in over 160 countries and a focus on integrated healthcare solutions, GE HealthCare plans to advance its strategic growth in the rapidly evolving medical technology sector.
Read more →Competitive Position
How GEHC ranks across every disease it competes inCompetitive Position is a premium feature
See how GEHC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial